CLC Number:
| [1] Stenehjem D, Tran D, Nkrumah M, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer[J]. Onco Targets Ther,2018, 2018(11):5973-5989. [2] Zavalishina LE, Andreeva YY, Olyushina EM, et al. Immunohistochemical study of the MSI phenotype of urothelial bladder cancer[J]. Arkh Patol, 2020, 82(1):5-14. [3] Fraune C, Simon R, Hube-Magg C, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass[J]. Urol Oncol, 2020, 38(5): 488-495. [4] Eckstein M, Hartmann A, Strissel P, et al. Comparative analysis of tumour mutational burden(TMB)prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer(UBC)[J]. Ann Oncol, 2019, 30(5): 376-377. [5] Tang X, Qian WL, Yan WF, et al. Radiomic assessment as a method for predicting tumor mutation burden(TMB)of bladder cancer patients: a feasibility study [J]. BMC Cancer, 2021, 21(1): 823-823. [6] Albandar HJ, Fuqua J, Albandar JM, et al. Immune-related adverse events(irAE)in cancer immune checkpoint inhibitors(ICI)and survival outcomes correlation: to rechallenge or not? [J]. Cancers,2021, 13(5): 989-991. [7] Kenichi C, Toshiaki U, Keisuke A, et al. PD1-1-5 Frequency of immune-related adverse events of immune-checkpoint inhibitors for non-small cell lung cancer in our single institution[J]. Ann Oncol, 2021, 32(4):325-325. [8] Rubino R, Marini A, Roviello G, et al. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy[J]. Endocr, 2021,74(1):172-179. [9] Lui DTW, Lee CH, Tang V, et al. Thyroid immune-related adverse events in cancer patients treated with anti-PD1/Anti-CTLA4 immune-checkpoint inhibitor combination: clinical course and outcomes[J]. Endocr Pract, 2021, 27(9): 886-893. [10] Kosuke N, Yosuke Y, Kenji K, et al. Primary lymphoepithelioma-like carcinoma of the esophagus with metastatic lymph node and gastric cancer[J]. Clin J Gastroenterol, 2021, 14(5): 1329-1336. [11] 李凯, 杨潇, 李鹏超, 等. 膀胱淋巴上皮瘤样癌1例报告[J].实用老年医学, 2021, 35(6): 636-637. [12] 范大铬, 黄海建, 吴春林. 膀胱淋巴上皮瘤样癌2例并文献复习[J].临床与实验病理学杂志, 2017, 33(10): 1153-1155. [13] Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder[J]. Am J Surg Pathol, 1994, 18(5): 466-473. [14] Serrano GB, Funez FA, Lopez RG, et al. Bladder lymphoepithelioma-like carcinoma: bibliographic review and case report[J]. Arch Esp Urol, 2008, 61(6): 723-729. [15] Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32): 33019-33032. [16] Alessandro R, Dalia RA, Giovanni B. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer[J]. Cancers, 2021, 13(3): 558-558. [17] Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer[J]. J Clin Invest, 2018, 128(10): 4441-4453. [18] 辇伟奇, 聂勇战, 应建明,等. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版)[J].中国癌症防治杂志, 2020, 12(5): 485-494. [19] Zhou F, Huang Y, Cai WJ, et al. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients[J]. Lung Cance, 2021, 15(3): 66-72. [20] Nalin L, Hong CS, Bindra RS. The role of mismatch repair in glioblastoma multiforme treatment response and resistance[J]. Neurosurg Clin N Am, 2021, 32(2): 171-180. [21] Machado-Neves R, Bernardo T, Elsa F, et al. Penile lymphoepithelioma-like carcinoma: a rare case with PD-L1 expression [J]. Int J Surg Pathol, 2021, 29(6): 690-692. |
| [1] | ZHANG De-qing, ZHU Yao-feng, MENG Hui, WANG Jun, LI Yan, SHI Ben-kang. Clinical observation on intravesical instillation of sodium hyaluronate for treatment of non-bacterial cystitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(1): 79-82. |
| [2] | ZHEN Hongtao1, ZHANG Huaiqiang1, XU Fuyu2, et al. Correlation of TRAIL expression with prognosis of bladder transitional cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 61-63. |
| [3] | . [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 122-124. |
|
||
